Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01014988 · ClinicalTrials.gov registry record · Phase 2
Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 202
- Enrollment target
NCT01014988 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 202 participants.
The verdict
NCT01014988, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 202 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether zanamivir aqueous solution given by intravenous injection is safe in treating hospitalized patients with confirmed influenza infection. A single arm open-label design has been selected to achieve the primary objective of providing regulatory authorities with safety data on IV zanamivir.
Interventions
- DRUG zanamivir aqueous solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2009-11 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01014988
The ClinicalTrials.gov registry entry for NCT01014988 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which zanamivir aqueous solution is the first listed.
NCT01014988 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01014988 about?
NCT01014988 is a clinical study titled "Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital". The purpose of this study is to determine whether zanamivir aqueous solution given by intravenous injection is safe in treating hospitalized patients with confirmed influenza infection. A single arm open-label design has been selected to achieve the primary objective of providing regulatory authorit...
What is the current status of trial NCT01014988?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 202 participants. The study started on 2009-11. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01014988?
The interventions under investigation include: zanamivir aqueous solution (DRUG).
Who is sponsoring clinical trial NCT01014988?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.